Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Economic burden associated with acute myeloid leukemia treatment.

Zeidan AM, Mahmoud D, Kucmin-Bemelmans IT, Alleman CJ, Hensen M, Skikne B, Smith BD.

Expert Rev Hematol. 2016 Jan;9(1):79-89. doi: 10.1586/17474086.2016.1112735. Epub 2015 Nov 14. Review.

PMID:
26568358
2.

Investigating the Evidence of the Real-Life Impact of Acute Hyperglycaemia.

Heller S, Houwing N, Kragh N, Ploug UJ, Nikolajsen A, Alleman CJ.

Diabetes Ther. 2015 Sep;6(3):389-93. doi: 10.1007/s13300-015-0126-y. Epub 2015 Aug 4.

3.

Humanistic and economic burden of painful diabetic peripheral neuropathy in Europe: A review of the literature.

Alleman CJ, Westerhout KY, Hensen M, Chambers C, Stoker M, Long S, van Nooten FE.

Diabetes Res Clin Pract. 2015 Aug;109(2):215-25. doi: 10.1016/j.diabres.2015.04.031. Epub 2015 May 6. Review.

4.

Factors Influencing Dutch Drug Reimbursement Recommendations; A Database Analysis.

Alleman CJ, Spoorendonk JA, Charokopou M, Hensen M, Heeg B.

Value Health. 2014 Nov;17(7):A441. doi: 10.1016/j.jval.2014.08.1155. Epub 2014 Oct 26. No abstract available.

5.

A Comparison of Factors Influencing Reimbursement and Coverage Decisions in Scotland (Smc), The Netherlands (Nzi) and Germany (G-Ba).

Charokopou M, Alleman CJ, Verleger K, Spoorendonk JA, Schmidt R, Schoeman O, Heeg B.

Value Health. 2014 Nov;17(7):A430. doi: 10.1016/j.jval.2014.08.1091. Epub 2014 Oct 26. No abstract available.

6.

Cost-analysis of treatment of childhood acute lymphoblastic leukemia with asparaginase preparations: the impact of expensive chemotherapy.

Tong WH, van der Sluis IM, Alleman CJ, van Litsenburg RR, Kaspers GJ, Pieters R, Uyl-de Groot CA.

Haematologica. 2013 May;98(5):753-9. doi: 10.3324/haematol.2012.073510. Epub 2013 Feb 12.

Supplemental Content

Loading ...
Support Center